The effects of bisphosphonates on osteoblasts in vitro

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 106, Issue 1, 2008, Pages 5-13

  Naidu, Aparna ^a   Dechow, Paul C ^a   Spears, Robert ^a   Wright, John M ^a   Kessler, Harvey P ^a   Opperman, Lynne A ^a  

^a BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45949086844     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.03.036     Document Type: Article

References (66)

1. Rogers M.J., Watts D.J., and Russel R.G. Overview of bisphosphonates. Cancer 80 (1997) 1652-1660
2. Coleman R.E. Setting new standards in bisphosphonates therapy. Am J Clin Oncol 25 (2002) S1-S2
3. Coleman R.E. Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol 25 (2002) S32-S38
4. Marx R.E., and Stern D. Oral and maxillo-facial pathology: a rationale for diagnosis and treatment. 1st ed. (2003), Quintessence, Chicago, IL p. 36-8
5. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1118
6. Migliorati C.A. Bisphosphonates and oral cavity avascular necrosis of bone. J Clin Oncol 21 (2003) 4253-4254
7. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
8. Marketos M. The top 200 brand drugs in 2003 (by units). Drug Topics 148 (2004) 76
9. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
10. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
11. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095-2105
12. Felix R., Guenther H.L., and Fleisch H. The subcellular distribution of 14C-dichloromethylenebisphosphonate and 14C-1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 36 (1984) 108-113
13. Boonekamp P.M., Van der Wee-Pals L.J., Van Wijk-Van Lennep M.M., Thesing C.W., and Bijvoet O.L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1 (1986) 27-39
14. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 4 (2000) 613-620
15. Zaki A.E., and Van Huysen G. Histology of the periodontium following tooth movement. J Dent Res 42 (1963) 1373-1379
16. Rygh P. Ultrastructural vascular changes in pressure zones of human periodontium incident to orthodontic movement. Acta Odontol Scand 31 (1973) 109-122
17. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055-1061
18. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M., et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8 (2002) 1080-1084
19. Vincenzi B., Santini D., Dicuonzo G., Battistoni F., Gavasci M., La Cesa A., et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25 (2005) 144-151
20. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostrate in castrated rats. Cancer Res 62 (2002) 6538-6544
21. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60 (2000) 6001-6007
22. Frediani B., Spreafico A., Capperucci C., Chellini F., Gambera D., Ferrata P., et al. Long term effects of neridronate on human osteoblastic cell cultures. Bone 35 (2004) 859-869
23. Pan B., To L.B., Farrugia A.N., Findlay D.M., Green J., Gronthos S., et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralization of human bone-derived cells in vitro. Bone 34 (2004) 112-123
24. Im G.-I., Qureshi S.A., Kenney J., Rubash H.E., and Shanbhag A.S. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25 (2004) 4105-4115
25. Mathov I., Plotkin L.I., Sgarlata C.L., Leoni J., and Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 16 (2001) 2050-2056
26. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., Grundker C., et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291 (2002) 680-686
27. Giuliani N., Pedrazzoni M., Negri G., Passeri G., Impicciatore M., and Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22 (1998) 455-461
28. Sahni M., Guenther H.L., Fleisch H., Collin P., and Martin T.J. Bisphosphonates act on rat bone resorption through mediation of osteoblasts. J Clin Invest 91 (1993) 2004-2011
29. Kantor M., Polson A.N., and Zander H.A. Alveolar bone regeneration after removal of inflammatory and traumatic factors. J Periodontol 47 (1976) 687-695
30. Polson A.M., Meitner S.W., and Zander H.A. Trauma and progression of marginal periodontitis in squirrel monkeys. III. Adaptation of interproximal alveolar bone to repetitive injury. J Periodontal Res 11 (1976) 279-289
31. Polson A.M., Meitner S.W., and Zander H.A. Trauma and progression of marginal periodontitis in squirrel monkeys. IV. Reversibility of bone loss due to trauma alone and trauma superimposed upon periodontitis. J Periodontal Res 11 (1976) 290-298
32. Thiebaud D., Sauty A., Burckhardt P., Leuenberger P., Sitzler L., Green J.R., et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61 (1997) 386-392
33. Dicuonzo G., Vincenzi B., Santini D., Avvisati G., Rocci L., Battistoni F., et al. Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res 23 (2003) 649-654
34. Ferretti G., Fabi A., Carlini P., Papaldo P., Cordiali Fei P., Di Cosimo S., et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69 (2005) 35-43
35. Darnay B.G., and Aggarwal B.B. Early events in TNF signaling: a story of associations and dissociations. J Leukoc Biol 61 (1997) 559-667
36. Pietschmann P., Stohlawetz P., Brosch S., Steiner G., Smolen J.S., and Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 63 (1998) 325-330
37. Sanders J.L., Tarjan G., Foster S.A., and Stern P.H. Alendronate/interleukin-1β cotreatment increases interleukin-6 in bone and UMR-106 cells: dose dependence and relationship to the antiresorptive effect of alendronate. J Bone Miner Res 13 (1998) 786-792
38. Bost K.L., Ramp W.K., Nicholson N., Bento J.L., Marriott I., and Hudson M.C. Staphylococcus aureus infection of mouse or human osteoblasts induces high levels of IL-6 and IL-12 production. J Infect Dis 180 (1999) 1912-1920
39. Marriott I., Gray D.L., Tranguch S.L., Fowler V.G., Stryjewski M., Scott Levin L., et al. Osteoblasts express the inflammatory cytokine Interleukin-6 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue. Am J Pathol 164 (2004) 1399-1406
40. Mackie P.S., Fisher J.L., Zhou H., and Choong P.F. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84 (2001) 951-958
41. Gao Y.-H., Shinki T., Yuasa T., Kataoka-Enomoto H., Komori T., Suda T., et al. Potential role of Cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem Biophys Res Commun 252 (1998) 697-702
42. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
43. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142; (2001) 5050-5055
44. Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
45. Quinn J.M., Itoh K., Udagawa N., Hausler K., Yasuda H., Shima N., et al. Transforming growth factor β effects on osteoclasts differentiation via direct and indirect actions. J Bone Miner Res 16 (2001) 787-794
46. Williams D.C., Boder G.B., Toomey R.E., Paul D.C., Hillman C.C., King K.L., et al. Mineralization and metabolic response in serially passaged adult rat bone cells. Calcif Tissue Int 30 (1980) 233-246
47. Dacy J.A. Effects of phosphated titanium and enamel matrix derivatives on osteoblast behavior in vitro. Master's thesis (2006), Texas A&M University Health Science Center, Dallas, TX
48. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) Published online ahead of print
49. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
50. Eriksen E.F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocrinol Rev 7 (1986) 379-408
51. Raisz L.G. Physiology and pathophysiology of bone remodeling. Clin Chem 45 (1999) 1353-1358
52. Fromigue O., Lagneaux L., and Body J.-J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15 (2000) 2211-2221
53. Forsea A.-M., Muller C., Riebeling C., Orfanos C.E., and Geilen C.C. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer 91 (2004) 803-810
54. Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 28 (2001) 35-44
55. Cheng Y.Y., Huang L., Lee K.M., Xu J.K., Zheng M.H., and Kumta S.M. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 75 (2004) 71-77
56. Garcia-Moreno C., Serrano S., Nacher M., Farré M., Díez A., Mariñoso M.L., et al. Effect of alendronate on cultured normal human osteoblasts. Bone 22 (1998) 233-239
57. Merck and Co. Fosamax (alendronate) package insert and prescribing information. White Hall Station, NJ; 2006.
58. Novartis Pharmaceuticals Corp. Zometa (zoledronic acid) injection. Concentration for intravenous infusion. Package insert and prescribing information. East Hanover, NJ; 2005.
59. Sells Galvin R.J., Gatlin C.L., Horn J.W., and Fuson T.R. TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 265 (1999) 233-239
60. Centrella M., Horowitz M.C., Wozney J.M., and McCarthy T.L. Transforming growth factor-beta gene family members and bone. Endocr Rev 15 (1994) 27-39
61. Centrella M., McCarthy T.L., and Canalis E. Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem 262 (1987) 2869-2874
62. Heine U.I., Munoz E.F., Flanders K.C., Roberts A.B., and Sporn M.B. Colocalization of TGF-beta1 and collagen I and III, fibronectin, and glycosaminoglycans during lung branching morphogenesis. Development 109 (1990) 29-36
63. Erlebacher A., Filvaroff E.H., Ye J.-Q., and Derynck R. Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell 9 (1998) 1903-1918
64. Opperman L.A., Adab K., and Gakunga P.T. Transforming growth factor-beta 2 and TGF-beta 3 regulate fetal rat cranial suture morphogenesis by regulating rates of cell proliferation and apoptosis. Dev Dyn 219 (2000) 237-247
65. Iwata K., Follet H., Phipps R.J., and Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39 (2006) 1053-1058
66. Allen M.R., Follet H., Khurana M., Sato M., and Burr D.B. Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tissue Int 79 (2006) 255-261